Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:40:56 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:KPTI from 2023-05-04 to 2024-05-03 - 37 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 16:30U:KPTINews ReleaseKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024
2024-05-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-24 16:01U:KPTINews ReleaseKaryopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
2024-04-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-06 16:05U:KPTINews ReleaseKaryopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
2024-03-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-29 07:30U:KPTINews ReleaseKaryopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
2024-02-22 07:00U:KPTINews ReleaseKaryopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
2024-02-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:30U:KPTINews ReleaseKaryopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
2024-01-03 07:00U:KPTINews ReleaseKaryopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-10 20:15U:KPTINews ReleaseKaryopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Na ƒ ¯ve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(
2023-12-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 16:05U:KPTINews ReleaseKaryopharm to Participate at Upcoming Investor Conferences
2023-11-06 07:00U:KPTINews ReleaseKaryopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
2023-11-02 09:20U:KPTINews ReleaseKaryopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
2023-11-02 07:30U:KPTINews ReleaseKaryopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-10-30 08:00U:KPTINews ReleaseKaryopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD ¢ „ ¢ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
2023-10-26 07:00U:KPTINews ReleaseKaryopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
2023-10-02 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-26 07:00U:KPTINews ReleaseKaryopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
2023-09-05 16:05U:KPTINews ReleaseKaryopharm to Participate at Upcoming Investor Conferences
2023-09-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-01 08:00U:KPTINews ReleaseKaryopharm Appoints Zhen Su, MD, MBA to its Board of Directors
2023-08-02 07:30U:KPTINews ReleaseKaryopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-08-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-26 07:00U:KPTINews ReleaseKaryopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
2023-07-25 15:00U:KPTINews ReleaseKaryopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
2023-07-19 08:00U:KPTINews ReleaseKaryopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
2023-07-17 16:05U:KPTINews ReleaseKaryopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
2023-07-05 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-28 08:00U:KPTINews ReleaseKaryopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Na ƒ ¯ve Myelofibrosis
2023-06-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-01 07:00U:KPTINews ReleaseKaryopharm to Participate at the Jefferies Healthcare Conference
2023-05-23 16:05U:KPTINews ReleaseKaryopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
2023-05-04 07:45U:KPTINews ReleaseKaryopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress